Palisade Bio (PALI) is now covered by HC Wainwright. They set a "buy" rating and a $7.00 price target on the stock.
Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating [Seeking Alpha]
Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients [Yahoo! Finance]
Palisade Bio Announces Participation in Two Upcoming Investor Conferences
Palisade Bio (PALI) is now covered by Stifel Nicolaus. They set a "buy" rating and a $5.00 price target on the stock.